Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

(Reuters) - The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Synergy's once-daily tablet, Trulance, is the company's first to win regulatory clearance.

However, the safety and effectiveness of the drug have not been established in patients less than 18 years of age, the FDA said. (

The company's shares were marginally down at $6.40 in extended trading. The stock had gained about 28 percent in one month.

CIC, which affects 14 percent of the global population, is a type of gastrointestinal disorder where individuals have difficult and infrequent bowel movements. It is called idiopathic because the cause is unknown.

Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C).

Synergy's Trulance, whose chemical name is plecanatide, is expected to generate peak sales of $348.8 million by 2021, according to Thomson Reuters Cortellis.

The drug is expected to compete against Ironwood Pharmaceuticals Inc's Linzess, which got approved in 2012 to treat IBS-C and CIC in the United States.

Linzess, which is sold by Allergan Plc and Ironwood in North America, AstraZeneca Plc in China, Hong Kong and Macau, Allergan in Europe and Astellas Pharma Inc in Japan, generated global sales of $464.7 million in the nine months ended Sept. 30.

(Reporting by Divya Grover, Dipika Jain and Komal Khettry in Bengaluru; Editing by Maju Samuel)


More Related News

Ford to recall about 1.3 million trucks in North America for door latch fix
Ford to recall about 1.3 million trucks in North America for door latch fix
  • US
  • 2017-10-18 15:52:20Z

Ford Motor Co said on Wednesday it would recall about 1.3 million 2015-17 Ford F-150 and 2017 Ford Super Duty trucks in North America to add water shields to side door latches at a cost of $267 million. The No.2 U.S. automaker said the safety recall is due to a frozen door latch or a bent or kinked

Bidding war heats up for $5 billion second Amazon HQ
Bidding war heats up for $5 billion second Amazon HQ

It's the prize of a lifetime -- a $5 billion investment creating 50,000 well-paid jobs that everyone wants, but only one US city will get. From East to West, from North to South, metropolises across the United States are locked in a frenzied bidding war desperate to woo Amazon into favoring them as the site of the e-commerce giant's second headquarters. From $7 billion in tax breaks in Newark, New Jersey -- 50 years ago aflame by deadly race riots -- to a giant cactus shipped inter-state, bids range from the colossally ambitious to the silly before Thursday's deadline for submissions.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Europe

Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.